关键词:

急性脑梗死, 依达拉奉右莰醇, 丁苯酞, 神经功能

Abstract:

Objective　To investigate the effect of edaravone dexcamphenol injection with concentrated solution combined with butylphthalide in the treatment of acute cerebral infarction. Methods　This was a retrospective study. A total of 76 cases of acute cerebral infarction in Affiliated Hospital of Xuzhou Medical University from January 2020 to October 2022 were selected and were divided into a conventional group and a treatment group according to different treatment methods with 38 cases in each group. In the conventional group, there were 20 males and 18 females; the age ranged from 39 to 81 years old, with a mean of (59.36±9.25) years old. In the treatment group, there were 21 males and 17 females; the age ranged from 38 to 80 years old, with a mean of (58.69±9.96) years old. The conventional group was treated with butylphthalide, and the treatment group was treated with edaravone dexcamphenol injection with concentrated solution combined with butylphthalide. The efficacy and neurological function indexes [National Institutes of Health Stroke Scale (NIHSS) score], Barthel indexes (BI), and Ability of Daily Living Scale (ADL) scores before treatment and 2 weeks after treatment were compared between the two groups. The statistical methods used were independent sample t test, paired t test, χ² test, and rank sum test. Results　The total effective rate of the treatment group was higher than that of the conventional group [94.74% (36/38) vs. 78.95% (30/38)], with a statistically significant difference (χ²=4.145, P=0.042). There was no statistically significant difference in the NIHSS score between the two groups before treatment (t=0.194, P=0.847). After 2 weeks of treatment, the NIHSS scores of both groups were decreased (both P<0.05), and the NIHSS score of the treatment group was lower than that of the conventional group [(12.37±3.12) points vs. (19.36±2.96) points, t=10.019, P<0.001]. Before treatment, there were no statistically significant differences in the BI and ADL scores between the two groups (t=0.233, P=0.817; t=0.337, P=0.737). After 2 weeks of treatment, the BI and ADL scores in both groups were higher than those before treatment (all P<0.05), the BI score [(22.98±3.58) points vs. (18.25±3.01) points, t=6.234, P<0.001] and ADL score [(84.21±8.92) points vs. (77.69±7.69) points, t=3.413, P=0.001] in the treatment group were higher than those in the conventional group. Conclusion　In the treatment of patients with acute cerebral infarction, edaravone dexcamphenol injection with concentrated solution combined with butylphthalide can effectively improve the therapeutic effect, neurological function, and daily living ability, which is worthy of popularization and application.

Key words:

Acute cerebral infarction, Edaravone dexcamphenol, Butylphthalide, Neurological function